ZA200002488B - Therapeutic formulation for administering tolterodine with controlled release. - Google Patents
Therapeutic formulation for administering tolterodine with controlled release.Info
- Publication number
- ZA200002488B ZA200002488B ZA200002488A ZA200002488A ZA200002488B ZA 200002488 B ZA200002488 B ZA 200002488B ZA 200002488 A ZA200002488 A ZA 200002488A ZA 200002488 A ZA200002488 A ZA 200002488A ZA 200002488 B ZA200002488 B ZA 200002488B
- Authority
- ZA
- South Africa
- Prior art keywords
- controlled release
- therapeutic formulation
- tolterodine
- formulations
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200002488B true ZA200002488B (en) | 2001-05-16 |
Family
ID=20412370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200002488A ZA200002488B (en) | 1998-08-27 | 2000-05-19 | Therapeutic formulation for administering tolterodine with controlled release. |
Country Status (13)
Country | Link |
---|---|
US (2) | US6517864B1 (fr) |
EP (1) | EP1105111B1 (fr) |
JP (1) | JP2002523446A (fr) |
AT (1) | ATE405254T1 (fr) |
AU (1) | AU758399B2 (fr) |
CA (1) | CA2341063C (fr) |
DE (1) | DE69939382D1 (fr) |
ES (2) | ES2353765T3 (fr) |
NZ (1) | NZ509928A (fr) |
SE (1) | SE9802864D0 (fr) |
TW (1) | TWI253349B (fr) |
WO (1) | WO2000012070A1 (fr) |
ZA (1) | ZA200002488B (fr) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU728395B2 (en) * | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
EP0957073A1 (fr) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Dérivés de 3,3-diphénylpropylamines |
SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
ATE216223T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Transnasaler transport bzw. impfung mit hochadaptierbaren trägern |
ATE216875T1 (de) | 1999-01-27 | 2002-05-15 | Idea Ag | Nichtinvasive impfung durch die haut |
DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
WO2001001962A1 (fr) * | 1999-07-05 | 2001-01-11 | Idea Ag. | Procede d'amelioration du transport a travers des barrieres semi-permeables compatibles |
DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
WO2003053292A1 (fr) * | 2001-12-20 | 2003-07-03 | Femmepharma, Inc. | Administration de medicaments par voie vaginale |
US7812010B2 (en) * | 2003-01-02 | 2010-10-12 | Femmepharma, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
US20040191345A1 (en) * | 2003-03-26 | 2004-09-30 | Fredrik Nicklasson | New formulations and use thereof |
DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
WO2005011683A1 (fr) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | Preparation pour absorption transdermique |
WO2006015299A2 (fr) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Dispositif multi-reservoir pour la delivrance de medicament transdermique et la detection |
KR20130069764A (ko) * | 2005-02-03 | 2013-06-26 | 교린 세이야꾸 가부시키 가이샤 | 경피 흡수형 제제 |
US10010494B2 (en) | 2005-10-19 | 2018-07-03 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
CN101472644B (zh) * | 2006-04-13 | 2014-04-23 | 纽帕特公司 | 递送抗偏头痛化合物的透皮方法和系统 |
AU2012261753B2 (en) * | 2006-04-13 | 2015-03-05 | Teva Pharmaceuticals International Gmbh | Transdermal methods and systems for the delivery of anti-migraine compounds |
JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
CA2674078C (fr) * | 2006-12-26 | 2012-03-20 | Femmepharma Holding Company, Inc. | Administration topique de danazol |
US20080193766A1 (en) * | 2007-02-13 | 2008-08-14 | Northern Nanotechnologies | Control of Transport to and from Nanoparticle Surfaces |
RU2492175C2 (ru) | 2007-04-02 | 2013-09-10 | Теракос, Инк. | Бензиловые производные гликозидов и способы их применения |
US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
BRPI0815708B8 (pt) | 2007-08-23 | 2021-05-25 | Theracos Sub Llc | composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição |
KR101188333B1 (ko) * | 2008-02-20 | 2012-10-09 | 에스케이케미칼주식회사 | 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염 |
US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
EP2307546A1 (fr) * | 2008-06-04 | 2011-04-13 | Coda Therapeutics, Inc. | Traitement de la douleur avec des composés de modulation de jonction communicante |
US8366600B2 (en) * | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
US8155737B2 (en) | 2008-06-19 | 2012-04-10 | Nupathe, Inc. | Pharmacokinetics of iontophoretic sumatriptan administration |
AU2009270936B2 (en) | 2008-07-15 | 2014-12-18 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
ME02702B (fr) | 2008-08-22 | 2017-10-20 | Theracos Sub Llc | Procédés de préparation d'inhibiteurs de sglt2 |
EP2379561B1 (fr) | 2008-11-25 | 2015-11-04 | University Of Rochester | Inhibiteurs de mlk et procédés d'utilisation |
US8697661B2 (en) | 2009-06-24 | 2014-04-15 | Christine Kritikou | Use of spinosyns and spinosyn compositions against herpesviridae viral infections |
KR20110001103A (ko) * | 2009-06-29 | 2011-01-06 | 에스케이케미칼주식회사 | 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물 |
US20110003000A1 (en) * | 2009-07-06 | 2011-01-06 | Femmepharma Holding Company, Inc. | Transvaginal Delivery of Drugs |
CN105748401A (zh) * | 2009-08-10 | 2016-07-13 | 泰华制药国际有限公司 | 用离子电渗疗法治疗恶心和偏头痛的方法 |
WO2011046927A1 (fr) * | 2009-10-13 | 2011-04-21 | Nupathe,Inc. | Procédés et systèmes d'administration de rizatriptan par voie percutanée |
IL210279A0 (en) | 2009-12-25 | 2011-03-31 | Dexcel Pharma Technologies Ltd | Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients |
KR101746204B1 (ko) | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
KR20110094858A (ko) * | 2010-02-18 | 2011-08-24 | 에스케이케미칼주식회사 | 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물 |
CN102858372A (zh) * | 2010-04-28 | 2013-01-02 | 久光制药株式会社 | 皮肤刺激抑制剂和经皮吸收制剂 |
WO2011149950A2 (fr) | 2010-05-24 | 2011-12-01 | University Of Rochester | Hétéroaryles bicycliques formant inhibiteurs de la kinase et procédés d'utilisation |
WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
JP5642790B2 (ja) * | 2010-08-03 | 2014-12-17 | 久光製薬株式会社 | 貼付剤及びその粘着力増強方法 |
EP2654757A1 (fr) | 2010-12-22 | 2013-10-30 | Entarco SA | Utilisation de spinosynes et de compositions de spinosynes en tant qu'agents anesthésiques locaux et en tant qu'agents antiarythmiques |
EP2675893B1 (fr) | 2011-02-18 | 2019-01-09 | The Scripps Research Institute | Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin cellulaire myélinisant |
JP6087839B2 (ja) * | 2011-12-27 | 2017-03-01 | 帝國製薬株式会社 | トルテロジン含有貼付剤 |
WO2013148736A1 (fr) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions et traitements basés sur la modulation de la cadhérine |
NZ701949A (en) | 2012-05-18 | 2016-07-29 | Otago Innovation Ltd | Combination treatments and compositions for wound healing |
JP6153135B2 (ja) | 2012-06-12 | 2017-06-28 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
US9895320B2 (en) | 2012-09-28 | 2018-02-20 | KM Transderm Ltd. | Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer |
US10485800B2 (en) | 2012-11-30 | 2019-11-26 | The University Of Rochester | Mixed lineage kinase inhibitors for HIV/AIDS therapies |
CN103142465B (zh) * | 2013-03-19 | 2014-10-22 | 长春健欣生物医药科技开发有限公司 | 一种托特罗定成膜水凝胶制剂及其制备方法 |
JP6566444B2 (ja) | 2014-03-19 | 2019-08-28 | カーザ グローバル エルエルシーCurza Global, Llc | 2−(アシルアミノ)イミダゾールを含む組成物および方法 |
US9987361B1 (en) | 2014-12-29 | 2018-06-05 | Noven Pharmaceuticals, Inc. | Compositions and method for sustained drug delivery by active transdermal technology |
WO2018184019A1 (fr) | 2017-03-31 | 2018-10-04 | Curza Global, Llc | Compositions et procédés comprenant des 2-aminoimidazoles substitués |
MX2021002002A (es) | 2018-08-23 | 2021-05-31 | Seagen Inc | Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit). |
US20230354981A1 (en) * | 2020-07-23 | 2023-11-09 | Kimberly-Clark Worldwide, Inc. | Method for modulating the bladder microbiome to improve bladder health |
KR20230104659A (ko) | 2020-11-08 | 2023-07-10 | 씨젠 인크. | 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체 |
KR20230165911A (ko) | 2021-04-09 | 2023-12-05 | 씨젠 인크. | 항-tigit 항체를 사용한 암의 치료 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
ES2137261T3 (es) | 1992-05-13 | 1999-12-16 | Alza Corp | Administracion transdermica de oxibutinina. |
AU728395B2 (en) * | 1996-07-19 | 2001-01-11 | Gunnar Aberg | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders |
CA2232435C (fr) * | 1996-08-09 | 2006-11-14 | Alcon Laboratories, Inc. | Systemes conservateurs pour compositions pharmaceutiques contenant des cyclodextrines |
SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
-
1998
- 1998-08-27 SE SE9802864A patent/SE9802864D0/xx unknown
-
1999
- 1999-08-26 US US09/763,654 patent/US6517864B1/en not_active Expired - Fee Related
- 1999-08-26 WO PCT/SE1999/001464 patent/WO2000012070A1/fr active IP Right Grant
- 1999-08-26 EP EP99946522A patent/EP1105111B1/fr not_active Expired - Lifetime
- 1999-08-26 AU AU58919/99A patent/AU758399B2/en not_active Ceased
- 1999-08-26 NZ NZ509928A patent/NZ509928A/en unknown
- 1999-08-26 ES ES99946521T patent/ES2353765T3/es not_active Expired - Lifetime
- 1999-08-26 AT AT99946522T patent/ATE405254T1/de not_active IP Right Cessation
- 1999-08-26 CA CA002341063A patent/CA2341063C/fr not_active Expired - Fee Related
- 1999-08-26 ES ES99946522T patent/ES2310942T3/es not_active Expired - Lifetime
- 1999-08-26 JP JP2000567189A patent/JP2002523446A/ja active Pending
- 1999-08-26 DE DE69939382T patent/DE69939382D1/de not_active Expired - Lifetime
- 1999-08-27 TW TW088114752A patent/TWI253349B/zh not_active IP Right Cessation
-
2000
- 2000-05-19 ZA ZA200002488A patent/ZA200002488B/xx unknown
-
2002
- 2002-11-22 US US10/301,719 patent/US7008637B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2310942T3 (es) | 2009-01-16 |
AU5891999A (en) | 2000-03-21 |
JP2002523446A (ja) | 2002-07-30 |
SE9802864D0 (sv) | 1998-08-27 |
EP1105111A1 (fr) | 2001-06-13 |
EP1105111B1 (fr) | 2008-08-20 |
ES2353765T3 (es) | 2011-03-04 |
DE69939382D1 (de) | 2008-10-02 |
NZ509928A (en) | 2003-08-29 |
TWI253349B (en) | 2006-04-21 |
CA2341063C (fr) | 2008-02-12 |
WO2000012070A1 (fr) | 2000-03-09 |
US6517864B1 (en) | 2003-02-11 |
ATE405254T1 (de) | 2008-09-15 |
AU758399B2 (en) | 2003-03-20 |
CA2341063A1 (fr) | 2000-03-09 |
US20030124179A1 (en) | 2003-07-03 |
US7008637B2 (en) | 2006-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200002488B (en) | Therapeutic formulation for administering tolterodine with controlled release. | |
ATE370737T1 (de) | Verwendung oraler formulierungen zur behandlung der weiblichen sexuellen störung | |
MXPA05004381A (es) | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. | |
HUP0100437A2 (hu) | Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására | |
TR200201317T2 (tr) | Sinerjistik kombinasyon. | |
SE9803986D0 (sv) | New compositions | |
NZ531406A (en) | Plaster for the treatment of dysfunctions and disorders of nail growth | |
CA2316349A1 (fr) | Compositions et procede pour la protection de la peau contre une immuno-suppression ou des lesions provoquees par les rayons uv | |
ATE323473T1 (de) | Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon | |
IS2803B (is) | Fentanýlsamsetning fyrir gjöf í nef | |
EP0200490A3 (en) | Compositions for noninvasive administration of sedatives, analgesics, and anesthetics | |
EP1414451A4 (fr) | Formulations d'agoniste opioide a antagoniste liberable et sequestre | |
KR960703009A (ko) | 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용 | |
IS2789B (is) | Lyfjablöndur sem innihalda mónóamínoxídasa B hemla | |
HUP0300833A2 (hu) | Gabapentin analogonok alvászavarok kezelésére | |
CA2401000A1 (fr) | Methode de traitement et de diagnostic de troubles respiratoires du sommeil et moyen destine a la mise en oeuvre de cette methode | |
ZA973444B (en) | Transdermally administered dextromethorphan as antitussive agents. | |
NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
BR0005797A (pt) | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados | |
NO20013414L (no) | Ny anvendelse av melagatran | |
BR0315482A (pt) | Composições farmacêuticas e formas de dosagem para liberações bucal e sublingual da tizanidina e métodos de administração da tizanidina de forma sublingual ou bucal | |
SE0004101D0 (sv) | New use | |
HK1068003A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
HUP0203050A2 (hu) | Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények | |
IS7899A (is) | Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról |